Protective role of carnitine in acetate metabolism in patients with uremia treated by haemodialysis;Ochronna rola karnityny w metabolizmie octanow u chorych z mocznica leczonych hemodializa

Polskie Archiwum Medycyny Wewnetrznej

Volumn 97, Issue 6, 1997, Pages 534-540

  Wanic Kossowska, Maria ^a,b  

^a Instytutu Chorob W   (Poland)

^b Klinika Nefrologii AM w Poznaniu   (Poland)

Author keywords

acetate containing fluid; hemodialysis; L carnitine

Indexed keywords

ACETIC ACID; ACYL COENZYME A; CARNITINE;

ADULT; ARTICLE; CARNITINE DEFICIENCY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; FEMALE; HEADACHE; HUMAN; HYPOTENSION; MALE; NAUSEA; UREMIA; VOMITING;

EID: 0030865971     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wanner C., Horl W.H.: Carnitine abnormalities in patients with renal insufficiency. Nephron, 1988, 50, 89.
2. Łysiak-Szydlowska W.: Fizjologiczna rola I-karnityny w organizmie człowieka - przyczyny i skutki jej niedoboru. Pol. Tyg. Lek.., 1988, 10, 337.
3. Spagnoli L.G., Palmier G., Mauriello A. i wsp.: Morphometric evidence of the trophic effect of L-carnitine on human skeletal muscle. Nephron, 1990, 55, 16.
4. Savica V., Bellinghieri G., Di Stefano C. i wsp.: Plasma and muscle carnitine levels in haemodialysis patients with morphological-ultrastructural examination of muscle samples. Nephron, 1983, 35, 232.
5. Armitage P.: Metody statystyczne w badaniach medycznych. PZWL, Warszawa, 1978.
6. Domański C.: Statystyczne testy nieparametryczne. PWE, Warszawa, 1979, 155.
7. Vinay P., Cardoso M., Tjedor A. i wsp.: Acetate metabolism during hemodialysis: metabolic considerations. Am. J. Nephrol., 1987, 7, 337.
8. Egan J.D., Wells I.C.: Acetate intolerance and an inhibitor of acetate utilization in hemodialysis patients. Clin. Chem., 1979, 25, 3, 383.
9. Fraser C.L., Arieff A.L.: Nervous system complications in uremia. Ann. Intern. Med., 1988, 109, 2, 143.
10. Sułowicz W.: Zaburzuenia neurologiczne. Dializoterapia w codziennej praktyce. Red. B. Rutkowski, Wyd. Med , Makmed., 1994, 233.
11. Yamakawa M., Yamamoto T., Kishimoto T. i wsp.: Serum levels of acetate and TCA cycle intermediates during hemodialysis in relation to symptoms. Nephron, 1982, 32.
12. Fagher B., Thysell M., Nilsson-Ehle P. i wsp.: The effect of C, 1-carnitine supplementation on muscle metabolism, neuropathy, cardiac and hepatic function in hemodialysis patients. Acta Med. Scand., 1982, 212, 115.
13. Mayer G., Graf M., Legenstein E., Linhart L., Auer B., Lohninger A.: L-carnitine substitution in patients on chronic hemodialysis. Nephron, 1989, 52, 295.
14. Rogerson M.E., Rylance P.B., Wilson R.: Carnitine and weakness in hemodialysis patients. NephroL Dial. Transplant., 1989, 4, 366.
15. Maeda K., Shinzato T., Kobayakawa H.: L-carnitine administration on short-chain fatty acids (acetic acid) and long-chain fatty acid metabolism during hemodialysis. Nephron, 1989, 51, 355.